Microtubule Control of Metabolism in Prostate Cancer
Abstract
We tested whether metabolic inhibitors, metformin or 2-deoxy-glucose, function synergistically with docetaxel to block prostate cancer cell proliferation. Cell proliferation curves allowed calculation of the combination index, a quantitative measure of drug interactions, for LNCaP or PC-3 cell lines. Data trended toward synergy between microtubule-targeted drugs and metabolic inhibitors. Synergy was consistently calculated at the ED50 for each drug, but the combination index often shifted toward antagonism at higher drug doses. Statistical analyses indicated that some drug combination data were not significantly different from either drug alone, reducing confidence in the overall conclusion of synergy.
Document Details
- Document Type
- Technical Report
- Publication Date
- Nov 01, 2013
- Accession Number
- ADA597853
Entities
People
- Lynne Cassimeris
Organizations
- Lehigh University